Analysis of the MASTER trial (Abstract 481) showed clonoSEQ's ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients

 
Data in more than 30

  • Analysis of the MASTER trial (Abstract 481) showed clonoSEQ's ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients

     

  • Data in more than 30 abstracts supports clonoSEQ as a standard of care in blood cancers, delivering relevant and timely clinical insights to physicians, patients and investigators